| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4626 | Sbi-0069332 | Novel potentiator of metabotropic glutamate receptors for use against neurological and psychiatric disorders |
|
| DCC4627 | Sbi-183 | Novel inhibitor of Quiescin Sulfhydryl Oxidase 1 (QSOX1), suppresses tumor cell growth in a Matrigel-based spheroid assay and inhibits invasion in a modified Boyden chamber, but does not affect viability of non-malignant cells |
|
| DCC4628 | Sbi4211 | Inhibitor of S100B which selectively kills melanoma; Amoebicidal diamidine |
|
| DCC4629 | Sbp-0636457 | Novel Smac mimetic, demonstrating potent cell-killing effects in several subtypes of breast, ovarian, and prostate cancer cell lines but only when the DR ligand TRAIL or another such apoptosis inducer is co-administered |
|
| DCC4630 | Sc-2001 | Novel obatoclax derivative, inducing apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation |
|
| DCC4631 | Sc-203885 | Potent inhibitor of checkpoint kinase 2 (Chk2) |
|
| DCC4632 | Sc-44463 | Matrix metalloproteinase (MMP) inhibitor, also acting as a collagenase inhibitor |
|
| DCC4633 | Sc-53228 | Second-generation leukotriene B4 receptor antagonist |
|
| DCC4634 | Sc-558 | Selective COX-2 inhibitor |
|
| DCC4635 | Sc-68376 | Potent and selective inhibitor of p38 MAP kinase |
|
| DCC4636 | Sc-75416 | Novel selective COX-2 inhibitor |
|
| DCC4637 | Scacer1 | Novel photoswitchable substrate for sphingomyelin synthase 2 (SMS2), enabling optical control of apoptosis and being ready for azide-alkyne click chemistry |
|
| DCC4638 | Scacer2 | Novel photoswitchable substrate for sphingomyelin synthase 2 (SMS2), enabling optical control of apoptosis and being ready for azide-alkyne click chemistry |
|
| DCC4639 | Scalaradial | Natural Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion Channels |
|
| DCC4640 | Sch-202596 | Natural selective non-peptide antagonist for the receptor GAL-1 |
|
| DCC4641 | Sch2-1-20 | Novel Inhibitor of the virus fusion to its cell receptor, targeting SARS-CoV-2 spike protein HR1 |
|
| DCC4642 | Sch2-1-27 | Novel Inhibitor of the virus fusion to its cell receptor, targeting SARS-CoV-2 spike protein HR1 |
|
| DCC4643 | Sch-23982 | Precursor for radioiosotopically labelled R(+)-SCH-23390 |
|
| DCC4644 | Sch-23985 | D1 dopamine receptor antagonist |
|
| DCC4645 | Sch-351591 | Novel, orally active phosphodiesterase 4 (PDE4) inhibitor |
|
| DCC4646 | Sch-43478 | Non-nucleoside antiviral agent, having potent and selective activity against herpes simplex virus type 2 (HSV-2) |
|
| DCC4647 | Sch-51866 | Potent and selective PDE1 and PDE5 inhibitor |
|
| DCC4648 | Sch-538415 | Novel Acyl_carrier_protein_synthase>acyl carrier protein synthase inhibitor; Inhibitor of growth of the bacteria Streptococcus_pneumoniae>Streptococcus pneumoniae and Neisseria_gonorrhoeae>Neisseria gonorrhoeae |
|
| DCC4649 | Sch-53870 | Inhibitor of p21-hRas nucleotide exchange in vitro |
|
| DCC4650 | sch-79687 | Novel histamine H3-receptor antagonist |
|
| DCC4651 | Sch-900822 | Novel potent and selective glucagon receptor antagonist |
|
| DCC4652 | Schembl12616233 | Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
| DCC4653 | Schembl1548848 | Novel inhibitor of vanilloid receptor subtype 1 (VR1) |
|
| DCC4654 | Schembl15939407 | Novel Lysine-Specific Demethylase 1 (LSD1) Inhibitor (IC50: 20nM) |
|
| DCC4655 | Schembl18320671 | Novel glucose transport inhibitor |
|
